ALM-502 / Almac Discovery - LARVOL DELTA

ALM-502: A Next Generation ADC for the Treatment of Drug Resistant and Hard to Treat Solid Tumours. (ESMO 2026) - No abstract available

ADC • Oncology • Solid Tumor

ALM-502: A highly effective ADC for solid tumor therapy - enhancing payload delivery through molecular design (AACR 2026) - "In benchmarking studies, ALM-502 consistently delivers improved efficacy over a full length DAR4 ADC on a payload equivalents basis, in both single dose and multi-dose studies.ALM-502 has an excellent PK profile in preclinical species together with strong developability and manufacturability characteristics. These features, coupled with an ultra-low immunogenicity profile mean that ALM-502 has the potential to deliver significantly improved patient outcomes across a range of solid tumor indications with high unmet need."

ADC • Bladder Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Solid Tumor • ALPG • ALPP